Reviewing Axsome Therapeutics (AXSM) and Its Competitors

Axsome Therapeutics (NASDAQ: AXSM) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Axsome Therapeutics to related businesses based on the strength of its profitability, earnings, analyst recommendations, risk, dividends, institutional ownership and valuation.


This table compares Axsome Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Axsome Therapeutics N/A -127.58% -73.83%
Axsome Therapeutics Competitors -6,408.55% -84.01% -35.63%

Earnings & Valuation

This table compares Axsome Therapeutics and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Axsome Therapeutics N/A -$27.20 million -2.50
Axsome Therapeutics Competitors $290.27 million $35.99 million 52.24

Axsome Therapeutics’ rivals have higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Axsome Therapeutics and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics 0 0 4 0 3.00
Axsome Therapeutics Competitors 957 3406 11910 239 2.69

Axsome Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 473.53%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.90%. Given Axsome Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than its rivals.

Insider & Institutional Ownership

23.6% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 35.2% of Axsome Therapeutics shares are held by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Axsome Therapeutics rivals beat Axsome Therapeutics on 7 of the 12 factors compared.

About Axsome Therapeutics

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply